Cornulin (CRNN) Variants And Uses Thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsClaudia Gonzaga-Jauregui, Kavita Praveen
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsClaudia Gonzaga-Jauregui, Kavita Praveen
Estimating the term…
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a loss-of-function cornulin (CRNN) protein. The disclosure also provides isolated and recombinant human loss-of-function cornulin protein variants that comprise a truncation at a position corresponding to position 79. The truncation, and the nucleic acid molecules encoding this change, associate with skin disorders such as, for example, psoriasis, eczema, or atopic dermatitis. The disclosure also provides methods for determining whether a subject has or has a risk of developing a skin disorder, based on the identification of such alterations in the nucleic acid molecules encoding CRNN. Subjects at risk for or who have a skin disorder may be treated with an agent effective to treat the skin disorder.
1-14. (canceled)
An alteration-specific probe or primer comprising a nucleic acid sequence which is complementary to a nucleic acid sequence of a nucleic acid molecule encoding a cornulin protein truncated at a position corresponding to position 79 according to SEQ ID NO:8, wherein the alteration-specific probe or primer comprises a nucleic acid sequence which is complementary to a portion of the nucleic acid molecule encompassing the codon which encodes a cysteine at the position corresponding to the position 69 according to SEQ ID NO:8.
16-20. (canceled)
A method of treating a subject with a therapeutic agent that treats or inhibits a skin disorder, wherein the subject has a skin disorder or is at risk of developing a skin disorder, the method comprising:
Dependencies are inferred from the claim text.